Sponsors (4)
This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
Prohibits the NIH Director from awarding any support (including grants, contracts, cooperative agreements, or technical assistance) for research that uses live animals unless that research is conducted within the United States, its states, territories, or possessions. The law cites concerns about billions in past NIH funding for animal research overseas and limited NIH inspection/oversight of foreign organizations as reasons for the change.
The bill increases transparency and brings NIH-funded animal research more fully under U.S. oversight—enhancing accountability and reducing misuse risks—but does so at the expense of international collaboration, higher costs for taxpayers and institutions, and potential delays to scientific progress.
Taxpayers and the public gain clearer transparency and stronger oversight of NIH-funded animal research, improving accountability and the integrity of federally funded studies.
Concentrating NIH-funded animal research in the U.S. increases direct oversight of facilities and reduces the risk that taxpayer-funded work could be misused or fall outside U.S. jurisdiction.
Researchers and U.S. science broadly: narrowing eligible research sites and cutting off some foreign projects will reduce international collaboration, disrupt project continuity, and risk slowing scientific progress and U.S. competitiveness.
Taxpayers, institutions, and hospitals could face materially higher costs because studies may need to be relocated, duplicated, or incur new compliance and audit expenses to meet domestic requirements.
Individual researchers and research trainees who conduct animal studies abroad risk losing NIH funding, which would reduce training, cross-border collaboration, and the pace of some projects.
Introduced May 19, 2025 by Richard Lynn Scott · Last progress May 19, 2025